Biotechnology company Allergy Therapeutics plc (AIM: AGY) announced on Wednesday that it has treated the first paediatric patient in its Phase III G308 trial, evaluating the long-term efficacy and safety of Grass MATA MPL for grass-induced allergic rhinitis.

This marks the first long-term subcutaneous allergen-specific immunotherapy trial for paediatric patients in the industry.

Grass MATA MPL, a subcutaneous immunotherapy, utilises MicroCrystalline Tyrosine adsorbed allergoids and Monophosphoryl-lipid A (MPL) to deliver six pre-season doses. Previous adult trials (G306) showed significant reductions in symptoms and medication use during peak pollen season, with a Marketing Authorisation Application already submitted in Germany.

This immunotherapy targets allergic rhinitis and rhinoconjunctivitis by reducing IgE reactivity while preserving T-cell responsiveness. The inclusion of MPL enhances immune modulation, promoting a shift from Th2 to Th1 immune responses.

Headquartered in the UK, Allergy Therapeutics is a global leader in allergy immunotherapies, offering proprietary and third-party products across nine European countries and additional markets via distribution agreements.